Pre-treatment hippocampal functioning impacts context renewal for cholinergic modulated exposure therapy

Area of Science:

• Neuroscience
• Psychiatry
• Virtual Reality Therapy

Background:

• Social anxiety disorder (SAD) with performance concerns is a significant clinical challenge.
• Virtual reality exposure therapy (VRET) shows promise for treating SAD.
• Cholinergic antagonists, like scopolamine, may modulate fear memory reconsolidation during VRET.

Purpose of the Study:

• To investigate the moderating role of hippocampal (HPC) functioning on treatment response to scopolamine-augmented VRET in individuals with SAD.
• To determine specific patient profiles that benefit from scopolamine intervention.

Main Methods:

• A randomized controlled trial involving participants with SAD receiving VRET.
• Interventions included placebo, scopolamine 0.5 mg, and scopolamine 0.6 mg.
• Hippocampal functioning was assessed as a moderator of treatment outcomes, measured by post-treatment context renewal (CX) and skin conductance response (SCR).

Main Results:

• Scopolamine treatment led to significantly less post-treatment context renewal (CX) compared to placebo.
• A dose-response relationship for enhanced HPC functioning individuals showed reduced fear at CX with scopolamine.
• Impaired HPC individuals receiving scopolamine (both doses) exhibited reduced fear at CX compared to placebo, indicated by SCR-to-CS onset.

Conclusions:

• Scopolamine augmentation of VRET appears effective in reducing fear responses in social anxiety.
• Hippocampal functioning influences the response to scopolamine, suggesting potential for personalized treatment strategies.
• Further research is needed to clarify the inconsistent findings across measures and optimize scopolamine's therapeutic application.